MaxCyte IPO Presentation Deck

Ability to Drive Complex Engineering Via Non-Viral Delivery for CRISPR-Engineered T Cells in Patients with Refractory Cancer A human phase 1 clinical trial was conducted at a leading US academic institution to assess the safety and efficacy of a multiplexed TCR T Cell Therapy using CRISPR ribonucleoproteins (RNPS) targeting TRAC, TRBC and PD-1 and transduced NY-ESO-1 TCR cells. The delivery of CRISPR RNPS targeting the three genes was enabled by the MaxCyte EXPERT Platform. The results showed 90% on-target editing efficiency of CRISPR RNPs targeting TRAC, TRBC and PD-1. July 2021 MaxCyte Gene Editing in an Efficient T Cell Manufacturing Workflow Leukapheresis | T Cell & Elutriation Day Activation 3 5 TRAC, TRBC & PD-1 RNP Electroporation 6 Expansion 10 TCR Transduction NY-ESO-1 TCR 16 Lentiviral Vector Rx Harvest, Formulation & Cryopreservation Customer generated data showed multiplex editing CONFIDENTIAL Table 1: Measurement of On-Target Editing Efficiency for Each Gene by Final Product On-Target Editing Efficiency (%) TRAC TRBC 96.1 96.8 97.0 Manufactured NYCE T Cell Product (subject ID) UPN07 UPN27 UPN35 UPN39 Average ± SD PDCD1 100.0 99.6 99.8 98.2 99.4 ± 0.8 99.6 99.1 99.1 96.7 98.6 ± 1.3 93.5 95.8 ± 1.6 33

View entire presentation